Evidence map›Paper›PMID 41184304›Full record

ArticleNature communications2025

Determination of key functional structures of an amorphous VHL-based SMARCA2 PROTAC.

Daria Torodii, Jacob B Holmes, Manuel Cordova, Pinelopi Moutzouri, Lotte van Beek, Fredrik Edfeldt, Erik Malmerberg, Stig D Friis, Johan R Johansson, Alexander G Milbradt and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. From prediction to performance:International journal of pharmaceutics: X · 2026
    Article
  2. Rapid Assignment of Chemical Shifts From Crystal Structures in Solid-State NMR.Angewandte Chemie (International ed. in English) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Daria Torodii *Institut des Sciences et Ingénierie Chimiques, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-5436-9503
Jacob B Holmes *Institut des Sciences et Ingénierie Chimiques, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-0137-8382
Manuel CordovaInstitut des Sciences et Ingénierie Chimiques, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Pinelopi MoutzouriInstitut des Sciences et Ingénierie Chimiques, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Lotte van BeekProtein Science, Structure & Biophysics, Discovery Sciences, AstraZeneca R&D, Cambridge, UK.ORCID http://orcid.org/0000-0001-9486-8916
Fredrik EdfeldtMechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Erik MalmerbergMedicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID http://orcid.org/0000-0001-9144-5352
Stig D FriisMedicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID http://orcid.org/0000-0003-4330-5173
Johan R JohanssonMedicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID http://orcid.org/0000-0002-5764-4881
Alexander G MilbradtProtein Science, Structure & Biophysics, Discovery Sciences, AstraZeneca R&D, Cambridge, UK.
Sten O Nilsson LillData Science & Modelling, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Benjamin MalfaitOral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden.
Staffan SchantzOral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden. Staffan.Schantz@astrazeneca.com.ORCID http://orcid.org/0000-0002-0136-4856
Lyndon EmsleyInstitut des Sciences et Ingénierie Chimiques, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. lyndon.emsley@epfl.ch.ORCID http://orcid.org/0000-0003-1360-2572

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 200020_212046Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) NCCR MARVEL
6 · The paper itself

Abstract

Proteolysis targeting chimeras (PROTACs) enable degradation of disease-related proteins via E3 ligase recruitment. PROTACs often do not easily crystallize, and they are usually formulated in amorphous forms. Determining the key interactions that stabilize the solid drug forms is of high interest. Here, we determine the complete atomic-level structure of an amorphous Von Hippel-Lindau (VHL)-based SMARCA2 PROTAC (PROTAC 2) using nuclear magnetic resonance (NMR) crystallography. We find that PROTAC 2 is more disordered as compared to previously studied amorphous formulations, and that the three functional units of the molecule have distinct structural types. In contrast to smaller drug molecules, where intermolecular hydrogen bonding interactions were found to be the main stabilization mechanism for the amorphous solid form, for PROTAC 2 we postulate that, in analogy to glassy polymers, the main stabilization mechanism is the entropic contribution introduced by the overall flexibility, especially in the linker region of the molecule. We also note that the most populated conformations found in the amorphous form differ from those of bound PROTAC 2 in the ternary protein complex as determined via X-ray crystallography. Our results provide insight into key structural features that stabilize amorphous formulations, specifically for molecules that can target proteins previously considered undruggable.

Indexed as

Transcription FactorsVon Hippel-Lindau Tumor Suppressor ProteinCrystallography, X-RayHumansHydrogen BondingMagnetic Resonance SpectroscopyModels, MolecularProtein ConformationProteolysisTranscription FactorsVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID41184304
PMCPMC12583731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.